Royalty Pharma RPRX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $718.23M+20.5% | $827.15M+11.4% | $702.62M-0.1% | $363.98M-44.7% | $596.08M-10.3% | ||
| -$477.87M-195% | -$847.8M-67.7% | -$958.31M+19.7% | -$311.98M+65.1% | $503.92M+682% | ||
| $50.1M-92.9% | $80.54M+53.1% | $146.49M+51.0% | $291.57M+264% | $708.78M— | ||
| -$272.67M+71.0% | -$299.6M— | —— | -$507.81M-144% | -$941.3M-344% | ||
| -$32.3M-120% | -$320.25M— | $307.04M— | -$455.81M-149% | $158.69M-56.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Royalty Pharma generate?
- Royalty Pharma (RPRX) generated $2.6B in operating cash flow over the trailing twelve months.
- Where does Royalty Pharma's cash flow data come from?
- Every line is extracted from Royalty Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
